Home » Topics » BioWorld Science, Dermatologic

BioWorld Science, Dermatologic
RSS

Connect begins phase I trial of CBP-174 for chronic inflammatory pruritus

May 26, 2021

Sonelokimab shows significant clinical benefit over placebo in patients with plaque psoriasis

May 26, 2021

Incyte initiates phase II study of INCB-054707 in nonsegmental vitiligo

May 21, 2021

First patients dosed in phase I study of PBI-100

May 21, 2021

Olix initiates phase II study of OLX-10010 as treatment of hypertrophic scars

May 21, 2021

China's NMPA approves phase I trial of InnoCare's TYK2 inhibitor ICP-332

May 19, 2021

Phase III trials of ruxolitinib in vitiligo meet endpoints

May 17, 2021

Dosing begins in phase II trial of CGB-400 for rosacea

May 14, 2021

Reistone begins phase III trial of oral SHR-0302 in moderate to severe atopic dermatitis

May 12, 2021

GBR-830 shows improvement at 16 weeks in patients with moderate to severe atopic dermatitis

May 11, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...